Hospitals & Doctors
Premium Hospitals Selected · Senior Experts Gathered, For Your Reassuring Health Journey
Lily ZHOU
Languages:
Internationally leading expert in CAR-T cell therapy, pioneer in precision treatment of hematologic malignancies.
Dr. Lily Zhou is the Director and Chief Physician of the Department of Hematology at Shanghai SinoAmerican Health Hospital, holding a Doctor of Medicine degree. She is a pioneer and leading figure in the international application of CAR-T cell therapy in China.
With over 20 years dedicated to hematologic oncology, she has made groundbreaking contributions in CAR-T cell therapy and risk-stratified targeted therapy for multiple myeloma, lymphoma, and leukemia, and has led the first cohort of international patients to receive CAR-T treatment in China.
She has extensive experience treating overseas patients from the UK, New Zealand, Singapore, and other countries, and is highly skilled in cross-cultural clinical communication, personalized treatment planning, international referral coordination, and remote consultations.
20+ Years of Practice
16 SCI Papers
UCSF Postdoc
First CAR-T for International Patients in China
Focus on Disease Treatment & Therapeutic Methods
| Disease | Treatment Method | Advantage |
|---|---|---|
| Multiple Myeloma | CAR-T Cell Therapy (BCMA Target) | Fully human BCMA CAR-T; overall response rate ~99%, complete response rate 82.4%, severe CRS incidence <5% |
| Diffuse Large B-Cell Lymphoma (DLBCL) | CAR-T Cell Therapy (CD19 Target) | CD19-targeted; complete response rate 60–90%, single infusion, avoids repeated chemotherapy |
| Acute Lymphoblastic Leukemia (ALL) | CAR-T Cell Therapy (CD19 Target) + Personalized Bridging Regimen | Combined immunotherapy + targeted therapy + radiotherapy during CAR-T manufacturing to control tumor burden, reducing post-infusion adverse events and relapse risk |
| Chronic Lymphocytic Leukemia (CLL) | Risk-Stratified Targeted Therapy | Individualized targeted drug regimen based on molecular subtyping and prognostic risk assessment, improving depth of response and survival |
| Mantle Cell Lymphoma | CAR-T Cell Therapy (CD19 Target) + Risk-Stratified Targeted Therapy | Targeted + immunotherapy combination strategy, improving response rate in refractory cases |
Target Patient Populations
- Patients with relapsed or refractory hematologic malignancies.
- Patients with late-stage disease unresponsive to three or more lines of therapy.
- Elderly patients unable to tolerate conventional chemotherapy.
- International patients requiring cross-border medical care.
Career Path
Career Milestones
Clinical practice in Hematology at Changhai Hospital and Changzheng Hospital (affiliated with Second Military Medical University)
University of California, San Francisco (UCSF), Department of Hematology/Oncology, Postdoctoral Fellow
Shanghai Jiahui International Hospital, Head of Hematologic Oncology & Deputy Director of Operations, Cancer Center
Invited keynote speaker at Cancer Society of New Zealand’s “In Pursuit 2025” conference; academic exchange with CAR-T R&D team at Malaghan Institute of Medical Research
Professional Memberships
American Society of Clinical Oncology (ASCO)
Transplantation Immunology Group, Experimental Diagnostics Committee, Chinese Society of Hematology
Shanghai Society of Hematology, Shanghai Medical Association
Hematology Translational Medicine Committee, Shanghai Pharmaceutical Profession Association
Hematologic Disease Rehabilitation Committee, Chinese Association of Rehabilitation Medicine
Clinical Highlights
CAR-T Therapy
Successfully completed CAR-T cell therapy for the first cohort of international patients in China, including patients from the UK, New Zealand, Singapore, and other countries.
International Patients
Treated overseas patients from more than five countries, all discharged successfully with favorable follow-up outcomes.
Multidisciplinary Team
Led the establishment of SinoAmerican Health’s CAR-T Therapy Center MDT team, with support from Cardiology, ICU, Pulmonology, and other specialties.
Academic Achievements
16
SCI Papers
2
National Grants
Multiple
International Multi-center Trials
3
ASH Abstracts
Professional Memberships
UCSF Multiple Myeloma Translational Medicine Fund
- National Natural Science Foundation of China (NSFC)
- Shanghai Pujiang Talent Program
- Chinese Medical Doctor Association Multiple Myeloma Special Fund
Representative Publications
Early Intervention with Tocilizumab for CRS in CAR-T Therapy
2023
Chinese Journal of Hematology
Clinical Safety and Efficacy of Zanubrutinib-Based Bridging Regimen in CAR-T Therapy for R/R DLBCL
2023
Chinese Journal of Hematology
Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma — ZUMA-7 Long-Term Survival Data Interpretation
NEJM Medical Frontiers
Multiple SCI Publications on Advances in Multiple Myeloma Diagnosis and Treatment
Academic Exchanges
- Multiple invitations to the American Society of Hematology (ASH) Annual Meeting; three abstracts accepted for poster presentations.
- Invited keynote speaker at Cancer Society of New Zealand's "In Pursuit 2025" conference.
- Established referral collaboration intent with the CAR-T R&D team at Malaghan Institute of Medical Research, New Zealand.
Get Your Free No-obligation Medical
Consultation Now